A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Risk Factors Summary Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factors summary, and other risks that we face, can be found in Part I, Item 1A “Risk Factors” and should be carefully considered, together with other information in this Annual Report and our other filings with the SEC before making investment decisions regarding our securities. Investing in our securities involves substantial risk. The risks described under Part I, Item 1A “Risk Factors” of this Annual Report may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant risks we face include the following: •There is no established U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -74M | -74M | -64M | -50M | -45M | -34M |
| EPS | $-0.80 | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Free Cash Flow | -62M | -62M | -69M | -37M | -44M | -33M |
| ROIC | -105.3% | -106.9% | -90.3% | -54.7% | -62.6% | -30.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -78M | -78M | -68M | -55M | -46M | -34M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -109.8% | -107.8% | -91.4% | -55.6% | -63.4% | -30.9% |
| Shares Outstanding | 93M | 93M | 74M | 54M | 68M | 53M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 10M | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 14M | 17M | 23M | 43M | 42M | 54M | 60M | 60M |
| SG&A | 9.4M | 9.1M | 11M | 14M | 13M | 14M | 18M | 18M |
| EBIT | -23M | -16M | -34M | -46M | -55M | -68M | -78M | -78M |
| Op. Margin | N/A | -152.2% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -24M | -16M | -34M | -45M | -50M | -64M | -74M | -74M |
| Net Margin | N/A | -155.2% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -78.9% | -51.3% | -30.9% | -62.6% | -54.7% | -90.3% | -106.9% | -105.3% |
| ROE | -111.4% | -51.3% | -30.9% | -63.4% | -55.6% | -91.4% | -107.8% | -109.8% |
| ROA | -65.2% | -41.9% | -29.2% | -47.3% | -41.8% | -66.1% | -78.1% | -79.7% |
| Cash Flow | ||||||||
| Op. Cash Flow | -20M | -15M | -33M | -42M | -33M | -69M | -62M | -62M |
| Free Cash Flow | -20M | -16M | -33M | -44M | -37M | -69M | -62M | -62M |
| Owner Earnings | -22M | -17M | -35M | -44M | -36M | -73M | -68M | -68M |
| CapEx | 79K | 202K | 192K | 1.6M | 4.2M | 65K | 77K | 77K |
| Maint. CapEx | 635K | 569K | 475K | 232K | 592K | 708K | 664K | 664K |
| Growth CapEx | 0 | 0 | 0 | 1.4M | 3.6M | 0 | 0 | 0 |
| D&A | 635K | 569K | 475K | 232K | 592K | 708K | 664K | 664K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 1.8M | 1.5M | 1.6M | 2.2M | 2.6M | 3.0M | 5.0M | 5.0M |
| Debt Repayment | 8.0M | 9.1M | 9.1M | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -4.9M | -23M | -107M | -65M | -96M | -70M | -77M | -9.2M |
| Cash & Equiv. | 9.2M | 17M | 2.3M | 10.0M | 23M | 11M | 11M | 11M |
| Long-Term Debt | 8.7M | N/A | 0 | 1.0M | 1.4M | 887K | 259K | 259K |
| Debt/Equity | 1.24 | 0.28 | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 |
| Interest Coverage | -20.5 | -51.7 | N/A | -859.3 | -319.3 | -495.7 | -825.8 | -825.8 |
| Equity | 21M | 32M | 109M | 71M | 91M | 70M | 67M | 67M |
| Total Assets | 36M | 39M | 116M | 96M | 121M | 97M | 93M | 93M |
| Total Liabilities | 15M | 7.2M | 6.4M | 25M | 30M | 27M | 26M | 26M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -322M | -339M | -372M | -418M | -468M | -532M | -606M | -606M |
| Working Capital | 19M | 30M | 108M | 67M | 87M | 67M | 65M | 65M |
| Current Assets | 32M | 36M | 114M | 81M | 103M | 82M | 80M | 80M |
| Current Liabilities | 13M | 5.9M | 6.0M | 14M | 16M | 15M | 15M | 15M |
| Per Share Data | ||||||||
| EPS | -7.03 | -1.77 | -1.77 | -1.60 | -0.94 | -0.86 | -0.80 | -0.80 |
| Owner EPS | -1.40 | -0.62 | -0.66 | -0.65 | -0.68 | -0.98 | -0.73 | -0.73 |
| Book Value | 1.32 | 1.14 | 2.06 | 1.05 | 1.69 | 0.94 | 0.73 | 0.73 |
| Cash Flow/Share | -1.25 | -0.55 | -0.62 | -0.62 | -0.62 | -0.93 | -0.67 | -0.79 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 16.0M | 27.8M | 53.2M | 67.8M | 53.6M | 74.4M | 92.6M | 92.6M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.2 | 1.2 | N/A | 0.8 | 0.9 | 4.0 | N/A | 1.2 |
| Price/Sales | N/A | 3.4 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -29.4% | -39.5% | N/A | -75.3% | -47.5% | -24.8% | N/A | -79.7% |
| Market Cap | 68M | 39M | 0 | 58M | 79M | 278M | 0 | 78M |
| Avg. Price | 5.36 | 3.93 | 0.00 | 3.81 | 1.88 | 2.07 | 0.00 | 0.84 |
| Year-End Price | 4.27 | 4.28 | 0.00 | 2.04 | 1.47 | 3.74 | 0.00 | 0.84 |
aTYR PHARMA INC passes 0 of 9 quality checks, indicating weak fundamentals.
aTYR PHARMA INC (ATYR) has a 5-year average return on invested capital (ROIC) of -69.1%. This is below average and may indicate limited pricing power.
aTYR PHARMA INC (ATYR) has a market capitalization of $78M. It is classified as a small-cap stock.
aTYR PHARMA INC (ATYR) does not currently pay a regular dividend.
aTYR PHARMA INC (ATYR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
aTYR PHARMA INC (ATYR) generated $-62 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
aTYR PHARMA INC (ATYR) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
aTYR PHARMA INC (ATYR) reported earnings per share (EPS) of $-0.80 in its most recent fiscal year.
aTYR PHARMA INC (ATYR) has a return on equity (ROE) of -107.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for aTYR PHARMA INC (ATYR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
aTYR PHARMA INC (ATYR) has a book value per share of $0.73, based on its most recent annual SEC filing.